 |
N-tert-butyl-3-[5-methyl-2-{[4-(2-pryyolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate |
|---|---|
| Trade Name | |
| Orphan Indication | Myelofibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2009-05-18 00:00:00 |
| Sponsor | Impact Biomedicines;12526 High Bluff Drive, Suite 260;San Diego, California, 92130 |
Related Access Program